Brief: Neurocrine Reports Late Stage Data Of Crenessity
08/05/2025 14:04
May 8 (Reuters) - Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES ANNOUNCES NEW RESULTS FROM EXPLORATORY ANALYSES OF THE PHASE 3 CAHTALYST™ PEDIATRIC STUDY DEMONSTRATING CRENESSITY™ REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING OR IMPROVING ANDROSTENEDIONE ACROSS PATIENT SUBGROUPS NEUROCRINE BIOSCIENCES INC - CRENESSITY REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING ANDROSTENEDIONE LEVELS NEUROCRINE BIOSCIENCES INC - DATA CONSISTENT ACROSS ALL PATIENT SUBGROUPS IN CAHTALYST STUDY NEUROCRINE BIOSCIENCES INC - CRENESSITY GENERALLY WELL TOLERATED IN CAHTALYST STUDY Source text: ID:nPn8gq8hNa Further company coverage: NBIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall